Address
37-24, Yuseong-daero 1628 beon-gil
Daejeon, 340-54
Korea (the Republic of)
Phone
82 4 2360 8880
Website
Sector
Healthcare
Industry
Biotechnology
Employees
94
First IPO Date
July 22, 2015
| Name | Title | Pay | Year Born |
| Ho-Il Choi | Chief Executive Officer | 0 | N/A |
Peptron, Inc. specializes in the creation of peptide-based pharmaceuticals designed to manage chronic health conditions. The company's technological expertise encompasses advanced long-acting drug delivery systems and SmartDepot, an ultrasonic spray-drying technique utilized for developing sustained-release injectable microsphere drug formulations. Their research and development pipeline features several key products: Luphere Depot, which addresses prostate cancer, endometriosis, uterine fibroids, and puberty-related issues; SR-Octreotide (PT201) for treating acromegaly; SR-Exenatide (PT302) for type 2 diabetes; and SR-Exenatide (PT320), which is aimed at Parkinson's and Alzheimer's diseases. Founded in 1997, Peptron, Inc. is headquartered in Daejeon, South Korea.